Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial

Welsh, Robert C; Sidhu, Robinder S; Cairns, John A; Lavi, Shahar; Kedev Sasko; Moreno, Raul; Cantor, Warren J; Stankovic, Goran; Meeks, Brandi; Yuan, Fei; Džavík, Vladimír; Jolly, Sanjit S

doi:10.1016/j.cjca.2019.04.026

Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial

Journal

The Canadian journal of cardiology

Date Issued

2019

Author(s)

Welsh, Robert C

Sidhu, Robinder S

Cairns, John A

Lavi, Shahar

Moreno, Raul

Cantor, Warren J

Stankovic, Goran

Meeks, Brandi

Yuan, Fei

Džavík, Vladimír

Jolly, Sanjit S

DOI

10.1016/j.cjca.2019.04.026

Abstract

Robust comparisons between oral P2Y12 inhibitors (clopidogrel, prasugrel, ticagrelor) in ST-elevation myocardial infarction (STEMI) patients who undergo primary percutaneous coronary intervention are lacking. We sought to evaluate outcomes on the basis of P2Y12 inhibitor therapy in patients from the Thrombectomy With PCI Versus PCI Alone in Patients With STEMI Undergoing Primary PCI (TOTAL) trial.